Abstract
Medical cancer research is at a new crossroads of science, technical progress, therapeutic advances, and new models of care, ethical issues and economic factors. In order to tackle these new approaches to cancer research and innovation, a series of discussions has led to our position paper which articulates a series of recommendations around three main axes: i. Switch to an open and collaborative model among public/private researchers, clinicians and manufacturers, starting at the early stage of innovation; ii. Use the power of the new technologies and tools of big data, computer and in silico modeling; iii. Support the emergence of new clinical trial designs and adapt accordingly the national policies for the faster adoption of innovations and access to patients. These three axes are closely interlinked and reflect fundamental values for the world of research: scientific cooperation, technical progress and contribution of science to a better society.